FTSE MIB
32.665,21 -944,64 (-2,81%) Dow Jones
38.589,16 -57,94 (-0,15%) Nasdaq
17.688,88 +21,32 (+0,12%) Nikkei 225
38.814,56 +94,09 (+0,24%) Petrolio
78,49 -0,13 (-0,17%) Bitcoin EUR
62.077,66 +290,78 (+0,47%)
HTGC Jan 2026 15.000 put
| Chiusura precedente | 1,2000 |
| Aperto | 1,2000 |
| Denaro | 1,2000 |
| Domanda | 1,5500 |
| Prezzo d'esercizio | 15,00 |
| Scadenza | 2026-01-16 |
| Min-Max giorno | 1,2000 - 1,2000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 154 |
GlobeNewswireX4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced the closing of a $115 million loan facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”). The company also announced that it drew down $22.5 million upon the transaction’s closing. “This expanded loan facility creates significant financial flexibility for X4 a
GlobeNewswireCOMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that the Company has entered into a term loan agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million. Kabir Nath, COMPASS Pathways Chief Executive Officer said, “COMPASS is pleased to partner with Hercules for this source of non-dilutive financing to support our COMP360 phas
